Etelcalcetide generic • Etelcalcetide has been approved by US FDA on Feb.2017 for the treatment of secondary hyperparathyroidism (HPT) in adults who suffer chronic kidney disease and undergo hemodialysis• Secondary hyperparathyroidism is a condition in which the body produces the excess parathyroid hormone in response to a low level of calcium in the blood which is usually observed in chronic kidney disease patients. • Etelcalcetide acts by activating the calcium-sensing receptor in the parathyroid gland and signals the body to produce less parathyroid hormone, thereby decreasing the level of calcium and phosphorus in the blood.
More Info about Etelcalcetide